Skip to main content
OpenTrials
Completed

NCT Number: NCT02192957

The Ottawa AF Cardioversion Protocol

Atrial fibrillation is an abnormal heart rhythm in which the top chambers of the heart (the atrial chambers) beat very fast. Electrical cardioversion is a technique to convert heart rhythm from AF to normal rhythm. The technique sends out a brief electric shock to the heart through electrodes (paddles or skin patches) applied to the outside of the chest wall. The shock resets the heart rhythm back to its normal pattern.

This technique is practiced at many hospitals, including the Heart Institute, and is not experimental. However no detailed national or international guidelines exist to assist physicians in performing cardioversion. Physicians use a variety of methods. Electrical cardioversion does not always restore normal rhythm. Adjusting the electrical energy dose, changing the electrode position and applying pressure to the electrodes may improve the success rate.

This study will look at the safety and efficacy of a protocol (step by step method) for electrical cardioversion. The protocol prescribes the electrical energy dose, the electrode position and the application of pressure to the electrodes the physician will use. The individual elements of the protocol (energy dose, electrode position and pressure application) are often used by physician in clinical practice but not necessarily in the step by step order.

The purpose of this study is to get all doctors to follow a standard protocol 'the Ottawa AF cardioversion protocol'. We think that using this protocol will improve overall cardioversion success rates. The results of this study may change usual practice in Canada and in other countries.

All supplies, equipment and medications used in the protocol cardioversion are approved by Health Canada.

We estimate that 389 participants from the University of Ottawa Heart Institute will be enrolled in the study over the next 2 years. The results will be compared with a group of previous patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Ottawa Heart Institution

Ottawa, Ontario, K1Y 4W7, Canada

About this study

Study design:

All eligible and consenting patients will undergo elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol.The fact that the physician follows the protocol makes this experimental. Aside from following the protocol, subjects will receive standard care before, during and after the procedure. Outcomes of the procedure and clinical features know to affect cardioversion efficacy will be collected. These will be compared to a group of 500 previous patients who underwent elective electrical cardioversion for AF at the Heart Institute.

Methodology:

The Ottawa AF protocol prescribes the electrical energy dose, the electrode position and the application of pressure to the electrodes the physician will use. The individual elements of the protocol (energy dose, electrode position and pressure application) are often used by physician in clinical practice but not necessarily in the step by step order.

The Ottawa AF protocol prescribes the following:

  • the starting energy dose (200 J) and electrode placement (anterior-posterior)
  • the second electrode placement (anterior-lateral) if the first shock is not successful
  • addition of pressure to electrodes if second shock is not successful
  • step up of energy dose (360 J) along with pressure to electrodes if third shock is not successful
  • optional further steps at physician's choice if fourth shock is not successful

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Documented atrial fibrillation within last 12 months
  • On continuous systemic oral anticoagulation for 28 days prior to the day of cardioversion or must have undergone a recent (< 48 hrs) trans-esophageal echocardiogram prior to the day of cardioversion
  • Able to provide informed consent

Exclusion criteria

  • Presence of intracardiac thrombus
  • Pregnancy

Treatment and study plan

Lifepak 20E Defibrillator, Licence No: 61944

Device

Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.

Ottawa AF Cardioversion

Other names: -HEARTSTART XL, Licence No: 24413., -Kendall 1010P Multi-function Defibrillation Electrodes, Licence No: 21857

Primary outcomes

  1. Last shock efficacy

    Time frame: immediately after cardioversion

    Last shock efficacy defined as success ( two or more beats of sinus rhythm) or failure.

Other outcomes

  1. Adverse Events

    Time frame: participants will be followed for the duration of hospital stay for elective cardioversion, an expected average of 2 hours.

    adverse events related to cardioversion

Sponsors and collaborators

Lead sponsor

David Birnie

Other

Registry information

Official study title

Developing a Standardized Atrial Fibrillation Cardioversion Protocol

Important dates

Study start
2015
Primary completion
2017
Study completion
2018
First posted
Jul 17, 2014
Registry last updated
Oct 2, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.